, Tracking Stock Market Picks
Enter Symbol:
Alexion Pharmaceuticals, Inc. (ALXN) [hlAlert]

Perform ALXN

Alexion Pharmaceuticals, Inc. (ALXN) rated Perform by Oppenheimer

Posted on: Wednesday,  Jan 20, 2010  8:25 AM ET by Oppenheimer

Alexion Pharmaceuticals, Inc.
(NASDAQ: ALXN) rated Perform by Oppenheimer.

Alexion Pharmaceuticals develops pharmaceutical products for the treatment of heart disease, and inflammation, diseases of the immune system and cancer in humans. The company's lead product candidates are genetically altered antibodies that target specific diseases which arise when the human immune system induces undesired inflammation in the human body. These candidates are designed to block components of the human immune system which cause undesired inflammation while allowing beneficial components of the immune system to remain functional.

OppenheimerFunds, Inc. has been helping investors achieve their financial goals since 1960. We are one of the nation's largest and most respected asset management companies. At OppenheimerFunds, we believe that in order for you to reach your financial goals, your investments must perform. That is why investment excellence—over the long term and across the range of our products—is our highest priority. OppenheimerFunds and its controlled affiliates offer a broad range of products and services to individuals, corporations and institutions, including mutual funds, separately managed accounts, investment management for institutions, hedge fund products, qualified retirement plans and subadvisory investment-management services.
Stock Market Advice
Date/Time (ET)SymbolRatingTermPrice (*)Target
1/24/2012 8:25 AM Buy
74.69 84.00
as of 12/31/2010
1 Week up  4.00 %
1 Month up  10.43 %
3 Months up  31.18 %
1 YTD up  18.08 %
Previous Recommendations
Date/Time (ET)SymbolRatingTermPrice (*)Target
9/27/2011 8:25 AM Buy
67.91 74.00
3/25/2011 8:25 AM Buy
23.75 26.00
10/21/2010 8:25 AM Buy
17.88 19.50
6/3/2010 8:25 AM Buy
13.22 15.50
1/20/2010 8:25 AM None

(*) Stock Price at the time of the recommendation.
RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy